COLLEGIUM PHARMACEUTICAL, INC (COLL)

Current Report Filed: 2026-05-07

Collegium Pharmaceutical announced Q1 2026 financial results on May 7, 2026, with earnings presentation accompanying the earnings release, indicating normal quarterly reporting cycle.
The filing is a routine 8-K for earnings disclosure under Item 2.02 and includes supplemental presentation materials under Item 7.01 Regulation FD Disclosure, typical for pharmaceutical company quarterly updates.
Signed by CFO Colleen Tupper, confirming proper corporate authorization and that financial results have been prepared and disclosed in accordance with SEC requirements.
No material events, significant guidance changes, strategic transactions, or leadership changes are indicated in this filing - it appears to be a standard quarterly earnings announcement.

Quarterly Report Filed: 2026-05-07

The filing contains multiple acquisition-related activities including the AZSTARYS acquisition completed on March 19, 2026, and the ongoing integration of the Ironshore acquisition from September 2024, indicating active portfolio expansion strategy.
Revenue recognition includes multiple branded pharmaceutical products (Belbuca, Xtampza ER, Jornay PM, Nucynta formulations, Symproic) with detailed allowance tracking for rebates, incentives, and chargebacks, suggesting complex commercialization and significant customer-managed pricing pressures.
The company maintains multiple license agreements (Grunenthal and Shionogi) with corresponding obligations and fair value considerations across different fair value measurement levels, indicating dependency on licensed assets for core revenue generation.
Equity compensation activity across employee stock options, RSUs, performance shares, and an employee stock purchase plan suggests active talent retention efforts, though details on option pricing and vesting schedules would require full document review for dilution impact assessment.

Current Report Filed: 2026-04-07

Collegium Pharmaceutical nominated Michael Donovan, a former EY audit partner with extensive life sciences industry experience, to stand for election to the board at the 2026 Annual Meeting.
John Fallon, a current board member since 2016, will not stand for re-election and will retire from the board at the 2026 Annual Meeting.
The board refreshment and succession planning does not appear to be due to any disagreement with the company, signaling an orderly transition.

Insider Trading Filed: 2026-04-03

The reporting person, David Dieter, who is the EVP & General Counsel of Collegium Pharmaceutical, Inc., disposed of 8,840 shares of the company's common stock to satisfy applicable withholding taxes upon the vesting of restricted stock units.
The transaction was executed on March 17, 2026, and Dieter still holds 68,231 shares of the company's common stock directly.
Insider transactions like this can provide insights into management's views on the company's stock and their confidence in its future performance.

Insider Trading Filed: 2026-03-20

The reporting person, Dieter David, sold 13,976 shares of the company's common stock on March 18, 2026, reducing their total beneficial ownership to 77,071 shares.
The sale was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 5, 2025.
The shares were sold at a weighted average price of $34.9241 per share, in multiple transactions ranging from $34.74 to $35.39 per share.

Current Report Filed: 2026-02-26

Collegium Pharmaceutical reported its Q4 and full-year 2025 financial results, indicating the company's performance during this period.
The earnings presentation provides additional details on the company's financial and operational performance, which investors may find useful.
There are no other material disclosures or events reported in this 8-K filing beyond the earnings announcement and presentation.

Annual Report Filed: 2026-02-26